The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2021Use of LRRK2 and Lysosomal Biomarker Signatures to Differentiate Idiopathic and Monogenetic Parkinson’s Disease
Study Rationale:
As new targeted therapies for Parkinson’s disease (PD) enter clinical trials, it will be important to develop biomarkers that will allow clinicians to match people with PD with... -
Target Advancement Program, 2021Validating Genetic Modifiers that Affect Disease Onset in People with LRRK2 Mutations
Study Rationale:
Mutations in the LRRK2 gene are a genetic cause of Parkinson’s disease (PD). However, the disease risk for carriers of LRRK2 mutations varies widely. Other genes — or genetic... -
Priority Biology, 2021Use of the Lipid BMP as a Surrogate Marker for LRRK2 and GCase Activity
Study Rationale:
Mutations in LRRK2 and GBA1 are common genetic risk factors for Parkinson’s disease (PD) and offer promising targets for the development of PD therapies. Identification of a... -
Priority Biology, 2021Efficacy of PRKN Gene Delivery toward Mitigation of Alpha-synuclein-induced Degeneration
Study Rationale:
Genetic mutations that cause the functional loss of the PRKN gene and its corresponding protein, parkin, can cause early-onset Parkinson’s disease (PD). Regardless of the cause... -
Aligning Science Across Parkinson's, 2021Engineering Research-enabling Cells to Fuel Mechanistic Studies of Parkinson’s Disease
Study Rationale:
Induced pluripotent stem cells (iPSCs) have become widely used in the research community to investigate how mutations found in genetic studies of Parkinson’s disease (PD) alter the... -
Therapeutic Pipeline Program, 2021Understand Me for Life: An Intelligibility App for Parkinson's Disease
Study Rationale:
Approximately 90% of people with Parkinson’s develop speech and language problems over the course of the disease, and more than half of these speakers experience problems with...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.